---
figid: PMC1839882__nihms14908f9
figtitle: Schematic illustration of the principal signaling pathways that are affected
  by sodium arsenite (As) treatment
organisms:
- Homo sapiens
- Mus musculus
organisms_ner:
- Mus musculus
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC1839882
filename: nihms14908f9.jpg
figlink: /pmc/articles/PMC1839882/figure/F9/
number: F9
caption: 'A schematic illustration of the principal signaling pathways that are affected
  by sodium arsenite (As) treatment. Arsenite accelerates activation of the MAPK pathways
  at the EGFR that finally up-regulates MAPK p38, ERK and JNK and the correspondent
  transcription factors of the AP-1 family: ATF2, c-Fos, c-Jun. Arsenite suppresses
  the JAK2-STAT3 and IKK-NF-κB signaling pathways and down-regulates expression of
  STAT3- and NF-κB-dependent anti-apoptotic genes. The third direction of the arsenic
  effects is linked with Rac1-NADPH oxidase activation, production ROS (superoxide),
  induction oxidative and genotoxic stress and initiation of the mitochondrial death
  pathway in some melanoma lines. At low doses (1–10 μM), arsenite preferentially
  plays a role of the regulator of cell signaling and gene expression, inducing expression
  and translocation to the cell surface TRAIL and its Receptor-1 and Receptor-2. This
  creates conditions for an induction of the TRAIL-mediated death pathway via paracrine
  mechanism and dramatically increases a susceptibility of arsenite-treated cells
  to the exogenous TRAIL. See additional explanation and references in the text.'
papertitle: Sodium arsenite accelerates TRAIL-mediated apoptosis in melanoma cells
  through upregulation of TRAIL-R1/R2 surface levels and downregulation of cFLIP expression.
reftext: Vladimir N. Ivanov, et al. Exp Cell Res. ;312(20):4120-4138.
year: ''
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9344236
figid_alias: PMC1839882__F9
figtype: Figure
redirect_from: /figures/PMC1839882__F9
ndex: 9a9c9f00-def9-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC1839882__nihms14908f9.html
  '@type': Dataset
  description: 'A schematic illustration of the principal signaling pathways that
    are affected by sodium arsenite (As) treatment. Arsenite accelerates activation
    of the MAPK pathways at the EGFR that finally up-regulates MAPK p38, ERK and JNK
    and the correspondent transcription factors of the AP-1 family: ATF2, c-Fos, c-Jun.
    Arsenite suppresses the JAK2-STAT3 and IKK-NF-κB signaling pathways and down-regulates
    expression of STAT3- and NF-κB-dependent anti-apoptotic genes. The third direction
    of the arsenic effects is linked with Rac1-NADPH oxidase activation, production
    ROS (superoxide), induction oxidative and genotoxic stress and initiation of the
    mitochondrial death pathway in some melanoma lines. At low doses (1–10 μM), arsenite
    preferentially plays a role of the regulator of cell signaling and gene expression,
    inducing expression and translocation to the cell surface TRAIL and its Receptor-1
    and Receptor-2. This creates conditions for an induction of the TRAIL-mediated
    death pathway via paracrine mechanism and dramatically increases a susceptibility
    of arsenite-treated cells to the exogenous TRAIL. See additional explanation and
    references in the text.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Map2k6
  - Map3k5
  - Dbf4
  - Arsk
  - Crk
  - Grap2
  - Syp
  - Mapk14
  - Ahsa1
  - Map2k3
  - Braf
  - Braf-rs1
  - Ephb2
  - Mapk1
  - Raf1
  - ras
  - Hras
  - Kras
  - Rem1
  - Mdk
  - Pik3r1
  - Map2k1
  - Map3k1
  - Akt1
  - Egfr
  - Atf2
  - Fos
  - Jun
  - Tnfsf10
  - Jak2
  - Stat3
  - Ikbkb
  - Chuk
  - Nfkb1
  - Cflar
  - Xiap
  - Fas
  - Fasn
  - Bcl2l1
  - Tnfrsf1a
  - Tnfrsf10b
  - Decr1
  - MAP2K6
  - DBF4
  - CRK
  - MAPK14
  - MAPK1
  - AIMP2
  - GRAP2
  - AHSA1
  - POLDIP2
  - MAPK11
  - MAPK12
  - MAPK13
  - MAP2K3
  - BRAF
  - EPHB2
  - MAPK3
  - RAF1
  - KRAS
  - HRAS
  - NRAS
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - MAP3K1
  - AKT1
  - AKT2
  - AKT3
  - EGFR
  - ATF2
  - GDNF
  - FOS
  - JUN
  - TNFRSF10A
  - TNFSF10
  - JAK2
  - STAT3
  - IKBKB
  - CHUK
  - NFKB1
  - CFLAR
  - XIAP
  - FAS
  - FASN
  - TNFRSF1A
  - TNFRSF10B
  - CYBA
  - CYBB
  - DUOX1
  - DUOX2
  - NCF1
  - NCF2
  - NCF4
  - NOX1
  - NOX3
  - NOX4
  - NOX5
  - RAC1
  - DECR1
  - CASP1
  - CASP2
  - CASP4
  - CASP5
  - CASP6
  - CASP8
  - CASP9
  - CASP10
  - CASP12
  - CASP14
  - CASP3
  - CASP7
  - lic
  - p38b
  - Nurf-38
  - Ebp
  - p38a
  - Hrb87F
  - p38c
  - Erk7
  - rl
  - Ras64B
  - Ras85D
  - Dsor1
  - Mtk
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Mekk1
  - Akt
  - Atf-2
  - CG44247
  - kay
  - Jra
  - as
  - IKKbeta
  - Dif
  - dl
  - Rel
  - Fas2
  - FASN1
  - Fas3
  - fand
  - tei
  - rg
  - FASN2
  - FASN3
  - wgn
  - Autoimmune lymphoproliferative syndrome
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
---
